What Drives Heart Failure with Preserved Ejection Fraction?
What Drives Heart Failure with Preserved Ejection Fraction?
Jennifer Ho, MD, discusses her team’s recent work showing strong association between obesity and pulmonary hypertension, and their ongoing research to understand the mechanisms driving this association.
Read more here:
Advances in Motion provides health care professionals with information about the latest breakthroughs, research and clinical advances from Massachusetts General Hospital.
Subscribe: https://pages.connect.massgeneral.org…
Content
8.37 -> Our lab is really interested in understanding
what drives heart failure with preserved ejection
12.84 -> fraction, or HFpEF.
13.84 -> And the overall hypothesis is really that
obesity leads to systemic inflammation which
20.49 -> can drive HFpEF in and of itself as a systemic
phenotype, and so our lab is really interested
26.61 -> in trying to elucidate systemic phenotypes
and how they contribute to heart failure with
31.77 -> preserved EF.
33 -> One of the current projects that we're really
excited about is that we're looking at a retrospective
39.44 -> cohort of about 9,000 patients that have been
seen at MGH, and have undergone right heart
47.3 -> catheterization.
48.3 -> And what we're studying in particular now
is how obesity is related to pulmonary hypertension.
54.01 -> Our findings show that there's a very strong
association with obesity and pulmonary hypertension
59.3 -> in specific, which we often see with HFpEF,
and so part of the ongoing research is now
67.36 -> to try to understand mechanisms driving this
association.
70.76 -> So what's on the horizon for us now is that
we want to extend the findings in the cross-sectional
76.33 -> study that we did showing a very strong association
between obesity and pulmonary hypertension.
80.86 -> And we're actually using cardiopulmonary exercise
testing to really bring out, or unmask, abnormal
87.43 -> pulmonary vascular function in patients with
HFpEF.
91.25 -> The other thing that we're bringing together
with this physiologic study is we're able
97.22 -> to isolate endothelial cells, fresh from human
patients, and we're able to study potential
103.39 -> cellular mechanisms that are driving this
process.
105.89 -> And so I think the ability to combine cell
based phenotyping with cardiopulmonary physiology,
112.11 -> I think is a really powerful way to try to
better understand patients with HFpEF.
Source: https://www.youtube.com/watch?v=URsLNZHKN_M